This did not reflect a general decrease in integrin expression since the surface expression of the integrin LFA-1's α-chain (CD11a) and β-chain (CD18) on CD4+ T-cells and CD8+ T-cells did not differ in untreated and natalizumab-treated MS-patients (Figure 1C). This evidence concerns the gene ITGAL and myeloid sarcoma.